AveXis is a biotechnology company focused on the development of gene therapies for the treatment of rare and life-threatening genetic diseases. The company leverages cutting-edge technology to create potentially curative gene replacement therapies for patients with serious genetic disorders.

AveXis

biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

Our Vision: To understand and use the therapeutic potential of the cannabis plant and thereby improve the quality of life for patients.Our Mission: To make cannabis-based medicines available to a wide patient population through the development of innovative, rigorously tested and regulator-approved products.

Metric
Company Name	AveXis	biosyn Arzneimittel GmbH
Symbol
MSH ID	COM:AVEXTRA	DE:BIOSYN
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	DE	DE
Stage
Employee Count	52
Website	avextra.com	biosyn.de
LinkedIn	avextra-ag	biosyn-arzneimittel-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AVEXTRA

AveXis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue